Close

Cerecor (CERC) Surges with Alkermes (ALKS) Following Positive Depression Trial Results

Go back to Cerecor (CERC) Surges with Alkermes (ALKS) Following Positive Depression Trial Results

Moody's Says Alkermes (ALKS) FORWARD-5 Data is Credit-Positive Development

October 21, 2016 2:31 PM EDT

Moody's Investors Service commented that the positive clinical data of Alkermes' (Nasdaq: ALKS) experimental depression drug ALKS-5461 is credit positive. There is no effect on Alkermes' ratings including the Ba3 Corporate Family Rating, or the negative rating outlook.

... More

Alkermes (ALKS) PT Raised to $70 at Leerink Partners

October 21, 2016 6:41 AM EDT

Leerink Partners analyst Paul Matteis reiterated an Outperform rating and raised its price target on Alkermes (NASDAQ: ALKS) to $70.00 (from $57.00) after the company announced positive results from their third ph3 study for ALKS5461 in depression.

Matteis commented, "We were previously... More